PTCT Q3 2023 Earnings — PTC Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

PTCTPTC Therapeutics, Inc.

$6B

Q3 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$197M-9.5% YoY

Gross Profit

$187M95.2% margin

Operating Income

-$118M-60.1% margin

Net Income

-$133M-67.6% margin

EPS (Diluted)

$-1.76

QoQ Revenue Growth

-8.1%

Cash Flow

Operating Cash Flow

-$15M

Free Cash Flow

-$44M

Stock-Based Comp.

$27M

Balance Sheet

Total Assets

$1.3B

Total Liabilities

$1.9B

Stockholders' Equity

-$671M

Cash & Equivalents

$165M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$197M	$217M	-9.5%
Gross Profit	$187M	$203M	-7.9%
Operating Income	-$118M	-$73M	-60.8%
Net Income	-$133M	-$109M	-21.6%

Revenue Segments

Manufacturing

$2M100%

Geographic Segments

Non-US

$77M53%

United States

$67M47%